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Abbreviations 
 
ACE  angiotensin converting enzyme 
AUC  area under the curve 
BOO  benign outlet obstruction 
BPE  benign prostatic enlargement 
BPH  benign prostatic hyperplasia 
CP  chronic prostatitis 
CPP  chronic pelvic pain 
CPPS  chronic pelvic pain syndrome 
CPSI  chronic prostatitis symptom index 
DW  distilled water 
EPIC  European Prospective Investigation into Cancer and Nutrition 
EPS  expressed prostatic secretion 
ICS  International Continence Society 
i.p.  intraperitoneal 
IUP  intraurethral pressure 
i.v.  intravenous 
LUTS  lower urinary tract symptoms 
MTOPS  Medical Therapy of Prostatic Symptoms 
NIH  National Institutes of Health 
PDE  phosphodiesterase 
p.o.  per os 
PSA  prostate specific antigen 
QOL  quality of life 
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REDUCE Reduction by Dutasteride of Prostate Cancer Events 
TURP  transurethral resection of the prostate 
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Introduction 
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Along with further advancement of life science and medical technology, it 
is expected that further cross-border medical care as well as changes in the 
demographics, globalization of society and economy will proceed in the future. 
Therefore, in the next 10 years, expectations for superior drugs are supposed to 
increase on a global scale along with further increase in awareness of health and 
life. Pharmaceutical industry has to continuously launch innovative medicines so 
as to contribute to the health and welfare of people around the world, which is its 
mission. 
Although the average life expectancy continues to increase in the world, 
the future of Japanese society which runs the top among them is being focused. It 
is a society that people can live a higher quality life, not just live longer, through 
proactive social participation or selection of a convincing medical and nursing care 
etc. 
Due to illness, aging, operations or anti-cancer agents, it is possible that 
people are constrained to their life, suffer from pain or can’t live by their own values. 
Now it is considered important, a medical care to respect patients’ outlook on life 
or sense of values and maintain their quality of life (QOL) as much as possible. 
Urogenital disorders such as lower urinary tract symptoms (LUTS) are one of the 
diseases relating to QOL. 
“LUTS” is a term that broadly means the symptoms associated with the 
storage and discharge of urine. LUTS is subjectively recognized by individuals who 
are usually patients but sometimes caretakers or partners. Symptoms are reported 
by patients or through interview. Normally it is qualitative, cannot be used for 
definitive diagnosis. LUTS is suggestive of a lower urinary tract dysfunction in the 
background but is also caused by urinary tract infection or the other etiology. 
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In the terminology of the International Continence Society (ICS) in 2002, 
the terms related to lower urinary tract function were revised and the part for LUTS 
was significantly revised (Abrams et al., 2002). LUTS includes major three 
symptoms, storage symptoms, voiding symptoms and post micturition symptoms, 
but also urogenital pain, genito-urinary pain syndromes or symptom syndromes 
(Table 1). 
There is no basic difference between the nature of LUTS in men and 
women. However, voiding symptoms such as slow stream are frequently found in 
men after middle age and urinary incontinence is apparently common in women. 
Storage symptoms other than urinary incontinence are somewhat frequently found 
in women but no difference, especially in the elderly has been reported in the most 
cases (Irwin et al., 2006, Schatzl et al., 2001, Kakizaki et al., 2002, Araki et al., 
2003, Terai et al., 2004, Homma et al., 2006). Prostate disease in men and stress 
urinary incontinence in women would have influence on the gender difference of 
the symptom frequency. 
To clarify the medical and social positioning of certain diseases and then 
establish a medical regime, information such as frequency, age distribution or 
medical care demand, that is, the epidemiological investigation is essential. 
European Prospective Investigation into Cancer and Nutrition (EPIC) study, which 
was conducted in Canada, Germany, Italy, Sweden and the United Kingdom in 2005 
is one of the examination of LUTS in compliance with the definition of the 
International Continence Society in 2002 (Irwin et al., 2006). Subjects of this study 
were 58,139 people of 18-70 years of age (analysis 19,165 people). Percentages 
having any LUTS were 62.5% in men and 66.6% in women, the storage symptoms 
59.2% in women and 51.3% in men, the voiding symptoms 25.7% in men and 
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19.5% in women, and post micturition symptoms 16.9% in men and 14.2% in 
women. In men, the frequency of all LUTS increased along with age and was quite 
significant in the 60 years of age or older. Also in women, the frequency of urgency, 
nocturia, urinary incontinence, slow stream, intermittent stream and post 
micturition dribble increased with age. 
Benign prostatic hyperplasia (BPH) is a disease in the QOL of elderly men 
and patients increases as become older and it is said that BPH is pathologically 
detected in 60-70% of men over 70 years of age (Berry et al., 1984). In BPH, 
hypertrophy nodule consisting of proliferative prostate epithelial cells and stromal 
cells is seen around the urethra and LUTS were caused by obstruction at lower 
urinary tract due to benign prostatic enlargement. That is, clinical BPH is composed 
of three elements of LUTS, benign prostatic enlargement (BPE) and benign outlet 
obstruction (BOO) (Figure 1). The concept of the classic BPH was the center the 
overlapping portions of these three circles, however, actual features of BPH is by 
no means simple. There are many cases without enlargement or obstruction in 
LUTS patients. 
Recently, an involvement of inflammation in prostate has been focused in 
BPH. In the clinical studies for 5α-reductase inhibitors, patients in the biopsy 
specimen of the prostate with inflammation findings showed large prostate volume, 
high symptom score (Nickel et al., 2008) and also high risk of urinary retention was 
reported in patients in the prostatectomy tissue with inflammation (Mishra et al., 
2007). It was speculated that changes in the hormonal environment associated with 
aging, chronic inflammation resulting from infection or enhancement of the 
immune response caused the remodeling of prostate structure and then prostate 
enlargement (Kramer et al., 2007). Some other recent studies have also suggested 
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that inflammatory infiltrate would lead to tissue damage and prolonged time to 
wound healing, which might subsequently induce prostatic enlargement (De 
Nunzio et al., 2012, De Nunzio et al., 2011, Alcaraz et al., 2009). 
For drug therapy of BPH (Table 2), currently, α1 blocker is firstly selected 
as the standard of care but in case the therapeutic effect of α1 blocker is insufficient 
and the volume of prostate is large, 5α-reductase inhibitors are used in combination 
with α1 blocker. Very recently, phosphodiesterase-5 (PED5) inhibitors became 
available and its blood flow improving effect, anti-inflammatory effect, afferent 
inhibitory effect other than main smooth muscle relaxant effects have been focused 
(Andersson et al., 2011). 
Prostatitis is seen in men of most of the generation unlike BPH but 
frequently in the elderly like BPH (Pontari, 2003). The classification of prostatitis 
by US National Institutes of Health (NIH) indicates that prostatitis is classified in 
category I-IV (Krieger et al., 1999) (Table 3). Category I is acute bacterial prostatitis 
and category II chronic bacterial prostatitis in both of which bacteria is detected. 
Category III is prostatitis in which bacteria is not proven and known as chronic 
prostatitis/ chronic pelvic pain syndrome (CP/CPPS), accounts for more than 90% 
of prostatitis. The Category III is further subdivided into IIIA (with inflammation) 
and IIIB (no inflammation). “Inflammatory” here means the fact that white blood 
cells are detected in the expressed prostatic secretion (EPS) after prostate massage 
or in the urine after massage. In addition, prostatitis which does not have symptoms 
but detects inflammation findings in prostate biopsy tissue specimens and expressed 
prostatic secretion, semen is classified as category IV, asymptomatic inflammatory 
prostatitis. 
Storage symptoms such as urinary frequency, feeling of incomplete 
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emptying and urgency are main symptoms of prostatitis but also voiding symptoms 
can be seen. Pain or discomfort in the various parts of perineum and pelvis is also 
main symptoms in Category III. In patients with Category III, there is a report that 
petechiae was detected by the bladder pressure expansion under anesthesia in its 
60% (Miller et al., 1995) or a report that its 84% of cases were positive in the 
potassium test used for examining the permeability of the urothelium (Parsons and 
Albo, 2002) so that some relation or overlap with symptoms and observations of 
interstitial cystitis is assumed. NIH-Chronic Prostatitis Symptom Index (NIH-
CPSI) has been created as an index to objectively quantify the symptoms of chronic 
prostatitis (Litwin et al., 1999). There is a possibility that chronic prostatitis is easily 
diagnosed for the cases of the young less than 50 years of age with storage 
symptoms, without neurological disease. In the cases of relatively young men with 
LUTS, interstitial cystitis or overactive bladder in addition to prostatitis needs to be 
carefully diagnosed. Cernitine pollen extract has been reported to have some 
efficacy in CP/CPPS but is not recommended drug therapy because of its weak 
evidence (Elist, 2006). 
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Kallikrein-kinin system plays an important physiological role as a 
circulation regulation through modulation of cardiovascular and renal function, and 
is also involved in inflammation such as asthma, rhinitis and arthritis, allergic 
diseases, pain, sepsis and tissue injury (Bhoola et al., 1992, Katori and Majima, 
1998, Wirth et al., 1995, Calixto et al., 2000). Bradykinin and kallidin (Lys-
bradykinin) are main kinins in mammals (Table 4, Figure 2) and produced through 
serine protease, specifically kallikrein, acting on kininogen. Normal life of 
bradykinin and kallidin in plasma is short and inactivated rapidly through 
degradation by enzyme mainly kininase II or angiotensin converting enzyme (ACE). 
When the arginine residues at the C-terminal side of bradykinin and kallidin are cut 
by kininase I (arginine decarboxypeptidase), des-Arg9-bradykinin and des-Arg10-
kallidin are respectively generated. These peptides act on bradykinin B1 receptor 
as an agonist, whereas bradykinin acts through B2 receptor and kallidin acts on both 
B1 and B2 receptors comparably. Bradykinin B1 receptor and B2 receptor have low 
homology, only 36% in humans (Menke et al., 1994, Marceau et al., 1998). 
Protease activation at the site of inflammation/tissue damage cleaves 
tissue/plasma kininogen precursors to release the nonapeptide bradykinin (Calixto 
et al., 2000, Dray and Perkins, 1993). Bradykinin is involved in a range of diverse 
biological functions including smooth muscle contraction, inflammation, pain, and 
mitogenicity, all of which are mediated by activation of either or both the B1 or B2 
receptors (Campbell, 2001, Howl and Payne, 2003). Bradykinin B2 receptors are 
expressed in a wide range of tissues, whereas B1 receptors are expressed at low 
levels under normal conditions and up-regulated following tissue 
damage/inflammation (Wirth et al., 1991, Ahluwalia and Perretti, 1999). 
All components of the kallikrein-kinin system exist in human male genital 
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secretions (Campbell, 2001), suggesting that these molecules participate in 
physiological and pathophysiological genitourinary function. Indeed, bradykinin 
has been detected in human prostate tissue as well as in the conditioned medium of 
human prostate-derived stromal cells in culture (Walden et al., 1999). Bradykinin 
has been shown to elicit contractile responses in isolated tissue obtained from the 
bladder, prostate, and urethra in many animal species (Schill and Miska, 1992, 
Srinivasan et al., 2004, Abdel-Hakim et al., 1983, Chopra et al., 2005, Watts and 
Cohen, 1991) (Figure 3).  
In addition, bradykinin involvement in the regulation of bladder function 
has been proven in studies demonstrating that both B1 and B2 receptor antagonists 
can reduce bladder overactivity in a rat model of cyclophosphamide-induced 
cystitis (Chopra et al., 2005) and in a rat model of spinal cord injury (Forner et al., 
2012). These previous findings indicate that bradykinin can evoke an inflammatory 
response and changes in the urinary bladder reflex either or both by directly 
activating B2 receptors on afferent fibers or indirectly by releasing ATP and other 
neurotransmitters of the urothelium (Chopra et al., 2005). 
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In order to examine bradykinin involvement via bradykinin B2 receptor in 
this study, I used FK3657, also known as FR173657 ((E)-3-(6-acetamido-3- 
pyridyl)-N-[N-[2,4-dichloro-3-[(2-methyl-8-quinolinyl) oxymethyl] phenyl]-N- 
methylaminocarbonylmethyl]acrylamide), a potent, selective, orally active and 
non-peptide bradykinin B2 receptor antagonist which was obtained by optimization 
of a lead compound discovered by random screening of Fujisawa pharmaceutical’s 
chemical library (Asano et al., 1997, Asano et al., 1999) (Figure 4). I firstly 
examined the physiological role of bradykinin in urethral function focusing on the 
voiding symptoms which are the main complaints of LUTS associated with BPH, 
and next examined the involvement of bradykinin in rat testicular pain model 
focusing on the testicular pain which is the main complaints of CP/CPPS. Finally, 
I discussed and concluded the physiological roles of bradykinin in LUTS and 
bradykinin B2 receptor as a potential novel therapeutic target. 
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Table 1. Classification of LUTS defined by ICS in 2002 (Abrams et al., 2002) 
1. Storage symptoms 
 Increased daytime frequency 
 Nocturia 
 Urgency 
 Urinary incontinence 
  Stress urinary incontinence, Urge urinary incontinence, Mixed urinary 
incontinence, Enuresis, Nocturnal enuresis, Continuous urinary 
incontinence, Other type of urinary incontinence 
 Bladder sensation 
  Normal, Increased, Reduced, Absent, Non-specific 
2. Voiding symptoms 
 Slow stream, Splitting or spraying, Intermittent stream (Intermittency), 
Hesitancy, Straining, Terminal dribble 
3. Post micturition symptoms 
 Feeling of incomplete emptying, Post micturition dribble 
4. Symptoms associated with sexual intercourse 
5. Symptoms associated with pelvic organ prolapse 
6. Genital and lower urinary tract pain 
 Bladder pain, Urethral pain, Vulval pain, Vaginal pain, Scrotal pain, Perineal 
pain, Pelvic pain 
7. Genito-urinary pain syndromes and symptoms syndromes suggestive of 
lower urinary tract dysfunction 
 Genito-urinary pain syndromes 
  Painful bladder syndrome, Urethral pain syndrome, Vulval pain 
syndrome, Scrotal pain syndrome, Perineal pain syndrome, Pelvic pain 
syndrome 
 Symptom syndromes suggestive of lower urinary tract dysfunction 
  Overactive bladder syndrome, Urge syndrome, Urgency-frequency 
syndrome, Lower urinary tract symptoms suggestive of bladder outlet 
obstruction 
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Figure 1. Three elements of clinical BPH (Hald, 1989) 
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Table 2. Recommended drug therapy for BPH 
α1 blocker 
Mechanism of action Inhibit the α1 adrenergic receptor that is involved in 
smooth muscle tone in the prostate and bladder neck, 
reducing the functional obstruction of the urethra by 
the prostate 
Name of drugs tamsulosin, naftopidil, silodosin etc. 
Note Standard of care (1st choice) 
5α-reductase inhibitor 
Mechanism of action Suppress the production of dihydrotestosterone by 
inhibiting the 5α-reductase, reducing the mechanical 
obstruction of the urethra associated with BPH 
Name of drugs dutasteride, finasteride (not approved in Japan) 
Notes In case the volume of prostate is large 
PED5 inhibitor 
Mechanism of action Inhibit the degradation of the local of cGMP by 
inhibiting the PDE5 in the smooth muscle cells of the 
urethra and prostate, relaxing smooth muscle 
Name of drugs tadalafil, sildenafil (not approved in Japan) 
Notes New option, recently approved 
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Table 3. Classification of prostatitis by NIH (Krieger et al., 1999) 
I. Acute bacterial prostatitis 
II. Chronic bacterial prostatitis 
III. Chronic prostatitis / chronic pelvic pain syndrome 
 IIIA.  Inflammatory 
 IIIB.  Non-inflammatory 
IV. Asymptomatic inflammatory prostatitis 
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Table 4. Mammalian kinins 
Bradykinin Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg 
Lys-bradykinin (kallidin) Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg 
des-Arg9-bradykinin Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe 
des-Arg10-kallidin Lys-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe 
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Figure 2. Chemical structure of bradykinin 
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Figure 3. Kallikrein-kinin system and physiological functions via B2 receptor 
(*PSA: prostate specific antigen) 
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Figure 4. Chemical structure of FK3657 
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Chapter 1 Physiological Roles of Bradykinin and 
Involvement of Bradykinin B2 Receptor in Urethral 
Function in Humans and Animals 
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1.1 Background 
BPH is a common disorder among middle-aged and elderly men which 
produces BOO. In these patients, LUTS characterized by poor stream, hesitancy in 
initiation of micturition, urinary frequency, nocturia and urgency were observed. 
α1-adrenoceptor antagonists are currently the first-line treatment for voiding 
dysfunction associated with BPH. Although BPH aetiology has not yet been fully 
elucidated, several mechanisms have been proposed as involved in the pathogenesis 
and progression of BPH (Gandaglia et al., 2013), and several recent studies have 
suggested a major role of prostatic inflammation in BPH pathogenesis and 
progression. Specifically, inflammatory infiltrate has been hypothesized to lead to 
tissue damage and prolonged time to wound healing, which might subsequently 
induce prostatic enlargement (De Nunzio et al., 2012, De Nunzio et al., 2011, 
Alcaraz et al., 2009).  
Protease activation at the site of inflammation/tissue damage cleaves 
tissue/plasma kininogen precursors to release the nonapeptide bradykinin (Calixto 
et al., 2000, Dray and Perkins, 1993). All components of the kallikrein-kinin system 
exist in human male genital secretions (Campbell, 2001) suggesting that these 
molecules participate in physiological and pathophysiological genitourinary 
function. Indeed, bradykinin has been detected in human prostate tissue as well as 
in the conditioned medium of human prostate-derived stromal cells in culture 
(Walden et al., 1999). In addition, bradykinin has been shown to elicit contractile 
responses in isolated tissue obtained from the bladder, prostate, and urethra in many 
animal species (Schill and Miska, 1992, Srinivasan et al., 2004, Abdel-Hakim et al., 
1983, Chopra et al., 2005, Watts and Cohen, 1991). However, few studies have 
20 
 
examined the pathophysiological roles of bradykinin in the lower urinary tract in 
humans or in vivo urethral function in animals. 
Here, to clarify the physiological roles of bradykinin and the involvement 
of bradykinin B2 receptor in urethral function in humans and animals, I investigated 
the effects of bradykinin in the urethral function in humans and animals using the 
bradykinin B2 receptor antagonist FK3657. 
  
21 
 
1.2 Materials and Methods 
1) Materials 
Bradykinin was purchased from PEPTIDE INSTITUTE, INC. (Osaka, 
Japan). FK3657 ((E)-3-(6-acetamido-3-pyridyl)-N-[N-[2,4-dichloro-3-[(2-methyl- 
8-quinolinyl) oxymethyl] phenyl]-N-methylaminocarbonylmethyl]acrylamide) 
synthesized at Astellas Pharma, Inc. (Tokyo, Japan), was dissolved in 0.1 N HCl 
and then diluted with distilled water. Phenylephrine hydrochloride and epinephrine 
hydrochloride were purchased from Sigma-Aldrich (St. Louis, MO, USA). 
 
2) Preparation of human urethral smooth muscle strips 
All human experiments were approved by the Human Ethical Committee 
of Astellas Pharma, Inc., and performed at the Astellas Research Institute of 
America. Urinary bladders examined were from three dead male donors who had 
consented to organ transplant donation or whose next of kin consented to donation 
of organs for research, and were purchased by a third party organ procurement 
agency (The International Institute for the Advancement of Medicine, Edison, NJ, 
USA). After the top, trigon, and mucosa of human urinary bladder were removed, 
a segment of proximal urethra was excised from a region 1-2 cm from the bladder 
neck. Connective tissue and the mucosa were removed by dissection. For isometric 
tension recording, strips approximately 10 mm in length were longitudinally or 
circumferentially prepared. The urethral smooth muscle strips were suspended in 
organ baths containing 25 mL of oxygenated Krebs-Henseleit solution (pH 7.4, 
118.4 mmol/L NaCl, 4.7 mmol/L KCl, 1.2 mmol/L KH2PO4, 1.2 mmol/L MgSO4, 
2.5 mmol/L CaCl2, 25.0 mmol/L NaHCO3, and 11.1 mmol/L glucose) at 37°C. The 
tension of the strips was measured isometrically with a force displacement 
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transducer coupled to a carrier amplifier and digitally recorded using a PowerLab 
(ADInstruments, Dunedin, New Zealand). 
 
3) Contractile response evaluation for human urethral smooth muscle strips 
Urethral tissue under a loading tension of 0.5 g was allowed to equilibrate 
for approximately 1 h, after which KCl was added to an organ bath at 100 mmol/L 
to confirm contractility. After washing the tissue several times with Krebs-
Henseleit solution and equilibrating for a further 30 min, a pre-contraction response 
for bradykinin (10 μmol/L) was obtained. Cumulative concentration-response 
curves for bradykinin (0.01-10 μmol/L) were obtained approximately 5 min after 
pretreatment with FK3657 (0.01-1 μmol/L) or its vehicle. The contractile responses 
were calculated as the percentage of bradykinin (10 μmol/L)-induced pre-
contraction. 
 
4) Measurement of intraurethral pressure in rats 
All animal experimental procedures were approved by the Committee for 
Animal Experiments of Astellas Pharma, Inc. Male Wistar rats (Charles River, 
Kanagawa, Japan; n=4) were anesthetized with urethane [1.2 g/kg, intraperitoneal 
(i.p.)]. A midline incision was made in the abdominal wall, and the urinary bladder 
was exposed. A 3.5-Fr sensor-tip transducer catheter (SPR-524; Millar Instruments. 
Inc., Houston, TX, USA) was inserted approximately 2 cm into the urethra through 
the superior aspect of the bladder so that the sensor-tip was located in the urethra 
of bladder neck (Figure 5), and the intraurethral pressure (IUP) was measured with 
a pressure amplifier (AP-601 G; Nihon Kohden, Tokyo, Japan) and digitally 
recorded using a PowerLab. For intravenous (i.v.) bolus injection, a polyethylene 
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catheter (PE-50) was inserted into a femoral vein. Following a stabilization period 
after surgery of at least 30 min, phenylephrine (30 μg/kg, i.v.) was injected to 
confirm an increase in IUP, and dose-response curves for bradykinin (0.003-
0.1 μg/kg, i.v.) were confirmed. FK3657 (0.03-1 mg/kg, i.v.) was then injected at 
increasing doses with approximately 30-min intervals, and the dose-response 
curves for bradykinin were obtained again 5 min after FK3657 injection. All agents 
were intravenously administered at 1 mL/kg. Area under the curve (AUC) of IUP 
for 60 sec after administration of phenylephrine or bradykinin was measured with 
a PowerLab. 
 
5) Surgical procedure and measurement of intraurethral pressure in dogs 
Three male beagle dogs weighing 11.7-16.0 kg were anesthetized with 
pentobarbital sodium (30 mg/kg, i.v.), which was continuously infused (4-
5 mg/kg/h) to maintain an anesthetic condition. After endotracheal intubation, 
animals were artificially ventilated using room air with a tidal volume of 20 mL/kg 
at a respiration rate of 20 breaths/min (respirator: SN-480-3; Shinano Co., Ltd., 
Tokyo, Japan). A midline abdominal incision was then made, and the urinary 
bladder was emptied using a catheter inserted into the bladder through its superior 
aspect to eliminate any potential effects of residual urine on IUP. A modified 
thermodilution balloon catheter (5-Fr; Nihon Kohden) was introduced into the 
urethra via the external urethral meatus. The balloon was then inflated with distilled 
water and placed in the prostatic urethra. The catheter was connected to pressure 
transducer (TP-400T; Nihon Kohden), and the IUP was measured using pressure 
amplifier (AP-601G; Nihon Kohden) and recorded on a paper chart (Figure 6). 
Another catheter was placed in a femoral vein for epinephrine, bradykinin, and 
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FK3657 administration. Measurements were taken following a stabilization period 
of at least 60 min after surgery. Epinephrine (3 μg/kg, i.v.) was injected to confirm 
an increase in IUP, and then the dose-dependent IUP response for bradykinin (0.3-
10 μg/kg, i.v.) and inhibitory effects of FK3657 (10-300 μg/kg, i.v.) on IUP change 
induced by 3 μg/kg bradykinin were evaluated. All agents were intravenously 
administered at 1 mL/kg. 
 
6) Data analysis 
Results are presented as mean ± standard error of mean (S.E.M). Data were 
statistically analyzed using SAS version 8.2 (SAS Institute, Tokyo, Japan). 
Differences between the FK3657 and vehicle groups were analyzed using Dunnett’s 
multiple comparison test. P ≤ 0.05 was considered statistically significant. 
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1.3 Results 
1) Bradykinin produced a contractile response in smooth muscle strips obtained 
from human urethra 
Bradykinin (0.01-10 μmol/L) induced contraction of urethra isolated from 
human in a concentration-dependent manner (Figure 7). The maximal response in 
human urethra was approximately 37% of the KCl (100 mmol/L) response 
(1.2±0.3 g, n=15). The bradykinin B2 receptor antagonist FK3657 (0.01-1 μmol/L) 
inhibited bradykinin-induced contraction concentration-dependently. 
 
2) Bradykinin induced an IUP elevation in rats which was reduced by FK3657 
In anesthetized rats, intravenously administered bradykinin (0.003-
1 μg/kg) dose-dependently increased IUP (Figure 8). The maximal response was 
close to that induced by the α1-adrenoceptor agonist phenylephrine (30 μg/kg, i.v., 
data not shown). FK3657 (0.03-1 mg/kg, i.v.) produced a rightward shift of the 
dose-response curve for bradykinin in rats. 
 
3) Bradykinin induced an IUP elevation in dogs which was reduced by FK3657 
In anesthetized dogs, intravenously administered bradykinin (0.3-
10 μg/kg) dose-dependently increased IUP (Figure 9). Figure 9a shows a typical 
trace of epinephrine- and bradykinin-induced IUP elevation in dogs. The maximal 
response was close to that induced by epinephrine (3 μg/kg, i.v.), although the 
response induced by 3 μg/kg bradykinin was considered submaximal (Figure 9b). 
As such, the dose of 3 μg/kg bradykinin was adopted to examine the effects of 
FK3657 on IUP in dogs. FK3657 (0.3-300 μg/kg, i.v.) inhibited bradykinin-induced 
(3 μg/kg, i.v.) IUP elevation in a dose-proportional manner, with a significant 
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reduction observed at 30 and 300 μg/kg (Figure 10). 
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1.4 Discussion 
In the present study, bradykinin concentration-dependently produced 
contractile responses in human urethral smooth muscle strips. The effect was 
subsequently inhibited by the bradykinin B2 receptor antagonist FK3657, 
suggesting that stimulation of bradykinin B2 receptors might contribute to the 
bradykinin-induced contractile response in human urethral smooth muscle. In 
addition, intravenous injections of bradykinin induced dose-dependent increases in 
IUP in both rats and dogs, with maximal responses closely resembling those 
induced by α1-adrenoceptor stimuli. The increases in IUP induced by bradykinin 
were also inhibited by FK3657 in a dose-dependent manner, which indicates that 
the contractile responses induced by bradykinin via bradykinin B2 receptor lead to 
increases in IUP in animals. These results are the first evidence demonstrating 
bradykinin and bradykinin B2 receptor involvement in urethral function in humans 
and animals, suggesting that bradykinin may induce an increase in IUP in humans 
via stimulation of bradykinin B2 receptors and potentially contributing to regulation 
of urethral resistance in humans. 
Bradykinin and bradykinin B2 receptor has been reported in the lower 
urinary tract in both neural and nonneural components and also reported to play an 
important role in normal and pathological conditions of urinary bladder function 
(Lecci et al., 1995, Maggi et al., 1993), as activation of the bradykinin B2 receptor 
stimulates detrusor muscle contractility and evokes bladder hyperreflexia (Lecci et 
al., 1995, Meini et al., 2000). These effects of bradykinin on bladder contractility 
may also occur via direct activation of pelvic afferent fibers (Lecci et al., 1995). 
Indeed, bradykinin B2 receptor antagonists have been reported to be effective in 
bladder overactivity in a model of chemically-induced cystitis (Chopra et al., 2005, 
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Maggi et al., 1993). However, little information is available on the 
pathophysiological roles of bradykinin in the lower urinary tract in humans or 
regarding in vivo urethral function in animals. While the present study demonstrated 
the contracting effect of bradykinin via its B2 receptors in human and animal 
urethral tissue, further studies will be required to clarify the functional roles of 
bradykinin in regulation of inflammatory and pain systems, including afferent C 
fiber activity, in the lower urinary tract. 
Recent in vitro, in vivo, and clinical studies have uncovered the crucial role 
of prostatic inflammation in BPH pathogenesis and progression, suggesting that 
infiltrating inflammatory cells might act as a link between hormonal changes and 
the remodeling process promoted by growth factors (Chughtai et al., 2011). 
Specifically, hormonal changes may induce an increase in inflammatory infiltrates 
in the prostate responsible for tissue damage at both the epithelial and stromal 
cellular levels, initiating a chronic process of wound healing which, in turn, might 
lead to prostatic enlargement (Sampson et al., 2007). Further, the prevalence of 
chronic prostatic inflammation in patients with LUTS associated with BPH as 
estimated in the REDUCE trial was 77.6% of 8,224 patients (Nickel et al., 2008). 
As mentioned above, bradykinin release is triggered by protease activation at the 
site of inflammation/tissue damage, and bradykinin has been detected in human 
prostate tissue as well as in conditioned medium of human prostate-derived stromal 
cells in culture (Walden et al., 1999). The present study showed the role of 
bradykinin in urethral function. Taken together, these previous findings and this 
study suggest that continuous release of bradykinin under conditions of chronic 
prostatic inflammation may be involved in voiding dysfunction in BPH patients 
who have prostatic inflammation. Further studies will be required to determine 
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levels of bradykinin in the prostate and the direct involvement of bradykinin in 
voiding dysfunction in patients with BPH. 
Here, I determined that extrinsic bradykinin induced contractile responses 
in human urethra and increases in IUP in rats and dogs but didn’t uncover the role 
of intrinsic bradykinin in urethral function in patients with voiding dysfunction. 
Also this study showed the role of bradykinin in urethral function only in male, and 
therefore further studies will be required for its role in urethral function in female. 
Although the experimental conditions used in this study may differ from those of 
clinical settings involving patients, our present findings suggest that inhibition of 
bradykinin-bradykinin B2 receptor signaling may be a novel target for treating 
voiding dysfunction associated with BPH in which an increase in intraprostatic 
bradykinin level is indicated. 
The present study provides evidence that bradykinin elicits urethral smooth 
muscle contraction via bradykinin B2 receptor, suggesting that bradykinin B2 
receptor antagonists may be useful in treating voiding dysfunction. 
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Figure 5. The way to insert the micro-tip transducer catheter from bladder to urethra 
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Figure 6. The way to measure IUP in anesthetized dogs 
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Figure 7. Concentration-dependent contraction induced by bradykinin (0.01-
10 μmol/L) in isolated human urethra and its inhibition by FK3657 (0.01-1 μmol/L) 
(mean ± S.E.M., n=2-6). Results are expressed as the percentage of bradykinin-
induced pre-contraction (10 μmol/L). 
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Figure 8. Dose-dependent increases in rat IUP induced by bradykinin (0.003-
1 μg/kg, i.v.) and the inhibitory effect of FK3657 (0.03-1 mg/kg, i.v.) on 
bradykinin-induced IUP increase in rats (mean ± S.E.M., n=4). Results are 
expressed as the per-minute change in IUP before and after FK3657 administration. 
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Figure 9. Dose-dependent increases in dog IUP induced by bradykinin (0.3-
10 μg/kg, i.v.) compared with that induced by epinephrine (3 μg/kg, i.v.); (a) typical 
traces of epinephrine- and bradykinin-induced IUP elevation in dogs, (b) results are 
expressed as the change in IUP before and after administration (mean ± S.E.M., 
n=3). 
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Figure 10. Inhibitory effect of FK3657 (0.3-300 μg/kg, i.v.) on bradykinin (3 μg/kg, 
i.v.)-induced IUP increase in dogs. Results are expressed as the change in IUP 
before and after FK3657 administration (mean ± S.E.M., n=3). * P < 0.05, ** 
P < 0.01 vs. vehicle group by Dunnet’s multiple comparison test. 
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Chapter 2 Intratesticular Bradykinin Involvement in 
Rat Testicular Pain Models 
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2.1 Background 
Chronic urogenital pain is a severe problem in urology, and chronic pelvic 
pain (CPP) disorders have been observed in a number of pelvic organs, possibly 
representing viscerovisceral referred pain. Symptoms of CPP disorders vary; for 
example, interstitial cystitis is characterized by suprapubic pain and increased 
urinary frequency and urgency (Teichman and Parsons, 2007), while CP/CPPS is 
characterized by pain across several organs, including perineum, penis, and lower 
abdomen, with discomfort during voiding or ejaculation. Some 40-50% of patients 
with CP/CPPS have reported pain or discomfort in the testes (Litwin et al., 1999, 
Schaeffer et al., 2002). CP/CPPS is also often accompanied by increased urinary 
frequency (Krieger et al., 1996). Several potential causes of these symptoms have 
been suggested, including abnormal activation of afferent nerves in the pelvis, 
neurogenic inflammation of pelvic nerves, pelvic floor spasticity, pelvic organ 
ischemia, and autoimmune reactions. However, the etiology remains uncertain, and 
no effective treatment has yet been developed. 
In addition to the genitourinary function of bradykinin described before, 
bradykinin involvement in the regulation of bladder function has been proven in 
studies demonstrating that both B1 and B2 receptor antagonists can reduce bladder 
overactivity in a rat model of cyclophosphamide-induced cystitis (Chopra et al., 
2005) and in a rat model of spinal cord injury (Forner et al., 2012). These previous 
findings indicate that bradykinin can evoke an inflammatory response and changes 
in the urinary bladder reflex either or both by directly activating B2 receptors on 
afferent fibers or indirectly by releasing ATP and other neurotransmitters of the 
urothelium (Chopra et al., 2005). 
While bradykinin has been recognized as a modulator of bladder smooth 
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muscle tone and as a prototypical mediator of increased pain sensation in both 
inflammatory and non-inflammatory bladder dysfunction, to our knowledge, 
relatively few studies have evaluated the role of bradykinin in urogenital pain. A rat 
model of testicular pain induced by injection of diluted acetic acid into the testes 
was recently established (Yoshioka et al., 2010). However, bradykinin involvement 
in testicular pain as well as this rat model has not yet been examined. 
Here, in order to evaluate bradykinin involvement in rat models of 
testicular pain, I examined whether or not an injection of bradykinin into the testes 
induces pain behaviors. I then assessed whether or not those pain behaviors, if 
present, might be inhibited by the bradykinin B2 receptor antagonist FK3657. In 
addition, I also examined the analgesic effect of FK3657 in a rat model of acetic 
acid-induced testicular pain and measured intratesticular concentration of 
bradykinin at several time points after acetic acid injection. 
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2.2 Materials and Methods 
1) Animals 
Male Wistar rats (Charles River, Kanagawa, Japan) were used. For 
behavioral tests and intratesticular bradykinin measurement, rats weighing 95-
180 g were used. All rats for behavioral tests were fasted the evening before 
experiments. All animal experimental procedures were approved by the Committee 
for Animal Experiments of Astellas Pharma, Inc., and followed the guidelines of 
the Committee for Research and Ethical Issues of the International Association for 
the Study of Pain. 
 
2) Materials 
Bradykinin was purchased from PEPTIDE INSTITUTE, INC. (Osaka, 
Japan) and diluted with distilled water (DW). Acetic acid was purchased from 
Kanto Chemical (Tokyo, Japan) and diluted with DW. FK3657 ((E)-3-(6-
acetamido-3-pyridyl)-N-[N-[2,4-dichloro-3-[(2-methyl-8-quinolinyl) oxymethyl] 
phenyl]-N-methylaminocarbonylmethyl]acrylamide) synthesized at Astellas 
Pharma, Inc. (Tokyo, Japan), was dissolved in 0.1 N HCl and then diluted with DW. 
 
3) Testicular pain model 
The behavioral test was performed in accordance with the method reported 
by Yoshioka et al. (Yoshioka et al., 2010). Briefly, a 27-gauge needle and 1-mL 
syringe were used to administer aqueous solutions of 0.1, 0.3, 1, 3, or 10 mmol/L 
bradykinin, aqueous solution of 1% acetic acid, or DW into the center of both the 
left and right testes (1 mL/kg each) of rats that were under conscious, but restrained, 
conditions. Rats were placed individually into a clear, round, plastic container 
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(diameter: 24.5 cm, height: 30 cm) for observation immediately after the injection. 
The following behavior was scored as a pain response: contraction of oblique 
musculature with inward flexion of the hind limb, stretching of the body, and 
flattening of the lower abdomen against the floor (Figure 11). In the time-course 
experiment, the number of pain responses 0-10 and 10-20 min after injection of 
bradykinin (0.1, 0.3, 1, 3, or 10 mmol/L) or DW were counted (n=4-6). In the 
evaluation of FK3657 pretreatment effect, only the number of responses from 0-
10 min after 1 mmol/L bradykinin injection or from 5-20 min after 1% acetic acid 
injection was counted (n=6-8 for bradykinin injection experiment, n=7-15 for acetic 
acid). FK3657 (1, 3, 10, or 30 mg/kg) or its vehicle (0.1 N HCl) was orally 
administered at 5 mL/kg 15 min before the injection of bradykinin or 10 min before 
acetic acid (Asano et al., 1997, Asano et al., 1999). 
 
4) Intratesticular bradykinin measurement 
To measure intratesticular bradykinin level, rats were sacrificed by 
exsanguination 5, 20, 40, or 60 min after the testicular injection of 1% acetic acid 
or DW (n=4). Immediately after laparotomy, testes were harvested, weighed, and 
frozen with dry ice. Frozen testes were then prepared in liquid nitrogen and crushed 
into powder by applying pulsed pressure using a Cryo-Press (Microtec Co., Ltd., 
Chiba, Japan). Crushed testes were deproteinized with 200 mg/mL trichloroacetic 
acid and then homogenized in the T-PER® Tissue Protein Extraction Reagent 
(Thermo Fisher Scientific KK, Kanagawa, Japan). After centrifugation, collected 
supernatant was neutralized, and the bradykinin concentration of each sample was 
measured using a MARKIT®-M Bradykinin ELISA assay kit (Dainippon Sumitomo 
Pharma Co., Ltd., Osaka, Japan). Results were presented as the amount of 
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bradykinin per wet weight of the testis. 
 
5) Data analysis 
Results are presented as mean ± standard error of mean (S.E.M). Data were 
statistically analyzed using SAS version 8.2 (SAS Institute, Tokyo, Japan) or 
GraphPad Prism version 5 (GraphPad Software Inc., San Diego, CA, USA). 
Differences in pain responses between the FK3657 and vehicle groups were 
analyzed using Dunnett’s multiple comparison test, and differences in bradykinin 
concentrations in testes between the 1% acetic acid and DW groups at 20 min after 
injection were analyzed using Student’s t-test. P ≤ 0.05 was considered statistically 
significant. 
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2.3 Results 
1) Intratesticular bradykinin injection induced pain behaviors 
Rats injected with aqueous solutions of 0.1, 0.3, 1, 3, or 10 mmol/L 
bradykinin in testes showed characteristic pain behaviors (Yoshioka et al., 2010), 
such as contraction of oblique musculature with inward flexion of the hind limbs, 
stretching of the body, and flattening of the lower abdomen against the floor. These 
behaviors appeared soon after injection, gradually diminishing over time, and were 
proportional to the concentration of bradykinin administered (0.1 mmol/L: 6.8±3.1, 
0.3 mmol/L: 5.6±1.4, 1 mmol/L: 9.5±1.5, 3 mmol/L: 10.0±0.7, 10 mmol/L: 6.2±2.9, 
Figure 12a). Injections of DW produced no responses (data not shown). Based on 
these findings, evaluation of the inhibitory effect by FK3657 was performed from 
0 to 10 minutes after injection of aqueous solution of 1 mmol/L bradykinin. 
 
2) FK3657 reduced intratesticular bradykinin injection-induced pain behaviors 
Oral administration of FK3657 dose-proportionally inhibited the pain 
behaviors induced by intratesticular injection of aqueous solution of 1 mmol/L 
bradykinin, with significant reduction observed at doses of 3, 10, and 30 mg/kg, 
respectively (3 mg/kg: 6.3±0.9 (P < 0.05), 10 mg/kg: 4.2±1.6 (P < 0.01), 30 mg/kg: 
2.0±0.7 (P < 0.01), Figure 13). 
 
3) FK3657 reduced intratesticular acetic acid injection-induced pain behaviors 
Oral administration of FK3657 dose-proportionally inhibited the pain 
behaviors induced by intratesticular injection of 1% acetic acid, with significant 
reduction observed at doses of 10 and 30 mg/kg (10 mg/kg: 4.0±1.7 (P < 0.01), 
30 mg/kg: 1.0±0.7 (P < 0.01), Figure 14). 
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4) Intratesticular acetic acid injection induced increases in intratesticular 
bradykinin 
Increases in intratesticular bradykinin concentration were detected soon 
after acetic acid injection, and further elevation was observed at 20 min after 
injection. Elevated bradykinin levels diminished to the level observed with DW 
injection within 40 min (at 20 min, 1% acetic acid: 2.64-3.64 ng/g-tissue, DW: 
1.08-1.37 ng/g-tissue, Figure 15). 
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2.4 Discussion 
In the present study, injection of aqueous solution of bradykinin into the 
testes of conscious rats produced characteristic pain behaviors (Yoshioka et al., 
2010), namely contraction of oblique musculature with inward flexion of the hind 
limb, stretching of the body, and flattening of the lower abdomen against the floor. 
Similar behaviors have been reported in other pain models, such as the artificial 
ureteral calculosis model, the visceral pain model induced by intracolonic 
administration of mustard oil or capsaicin, writhing tests, and the testicular pain 
model induced by intratesticular injection of acetic acid (Yoshioka et al., 2010, 
Giamberardino et al., 1995, Laird et al., 2001, Ikeda et al., 2001). The frequency of 
these bradykinin-induced behaviors was reduced dose-proportionally by FK3657, 
indicating that the pain behaviors were caused by bradykinin via its B2 receptor. In 
addition, FK3657 dose-dependently inhibited the pain responses induced by 
intratesticular injection of 1% acetic acid, and the fact that intratesticular bradykinin 
was released after its injection supported the exertion of its inhibitory effect via 
bradykinin B2 receptor. I preliminarily confirmed that the doses of FK3657 tested 
in the present study were well-tolerated in rats even after multiple administrations 
for 13 weeks (data not shown). The dose and timing of FK3657 administration were 
determined based on the previous studies, its pharmacokinetics (Tmax shorter than 
30 min, data not shown) and the observation period of pain behavior in these models. 
Indeed, pretreatment is not realistic in clinical setting and further studies will be 
required to investigate a therapeutic effect of FK3657. 
Writhing tests with intraperitoneal injection of acetic acid in rodents have 
been widely used to evaluate efficacy of analgesics against visceral pain. The pain 
behaviors induced by intratesticular injection of 1% acetic acid were recently 
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confirmed and found to be reduced by pretreatment with indomethacin and 
capsaicin, which indicates that the behaviors may reflect inflammatory pain 
associated with prostaglandins and are mediated by primary afferent C fibers 
(Yoshioka et al., 2010). In addition, the testes had obvious tissue damage and 
increased weight after 1% acetic acid injection, suggesting that inflammation 
occurred during the observation period. Protease activation at the site of 
inflammation/tissue damage cleaves tissue/plasma kininogen precursors to release 
bradykinin (Calixto et al., 2000, Dray and Perkins, 1993), which has been 
recognized as potent stimulator of afferent nerve fibers and probably the most 
potent endogenous algesic substance (Juan and Lembeck, 1974). I demonstrated a 
significant inhibitory effect of FK3657 in our model of acute inflammatory pain 
associated with activation of afferent C fibers, which was supported by the fact that 
most of the acute inflammatory effects of bradykinin, including pain, were 
considered to be induced via activation of bradykinin B2 receptors (Bathon and 
Proud, 1991, Hall, 1992). In addition, inhibitory effects of bradykinin B2 receptor 
antagonists against bladder overactivity as well as pain response were reported in a 
rat model of cystitis previously (Chopra et al., 2005, Maggi et al., 1993). Indeed, 
intratesticular injection of 1% acetic acid induced bladder overactivity as well 
(Yoshioka et al., 2010) but I didn’t examine the effect of bradykinin B2 receptor 
antagonist on it nor check whether intratesticular injection of bradykinin would 
affect the bladder function. Further studies will be required to determine the levels 
of bradykinin not only in the testes but also in the prostate and the involvement of 
bradykinin in regulation of pain or bladder overactivity in patients with CP/CPPS. 
CP/CPPS, Category III prostatitis (NIH classification) constitutes the vast 
majority (more than 90%) of cases and is further divided into IIIA and IIIB 
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subcategories, based on respective presence or absence of evidence of inflammation 
(white blood cell counts in urine specimen after prostate massage, seminal plasma, 
or expressed prostatic secretions) (Krieger et al., 1999). Prostatic inflammation has 
been reported in 33% of patients with CP/CPPS who underwent transperineal 
prostate biopsy (True et al., 1999), and abnormal levels of inflammatory cytokines 
have also been reported (Pontari and Ruggieri, 2004). Such chronic inflammation 
is considered to enhance the activity of afferent C fibers, including pain which is 
the symptom that distinguishes CP/CPPS from other voiding dysfunctions (Krieger 
et al., 1996). Given that bradykinin has been detected in human prostate tissue as 
well as in the conditioned medium of human prostate-derived stromal cells in 
culture (Walden et al., 1999), elevated bradykinin levels in the prostate due to 
chronic inflammation likely contribute to pain in patients with CP/CPPS. The pain 
behavior induced by intratesticular injection of 1 mmol/L bradykinin disappeared 
at 20 min and that by 1% acetic acid at 1 h, from which these models were 
considered acute urogenital pain models. I didn’t examine the effect of bradykinin 
B2 receptor antagonist in chronic inflammatory urogenital pain model which is 
considered closer to the state of the patients with CP/CPPS. Further studies will be 
required to determine whether bradykinin B2 receptor antagonist is effective for 
pain in patients with CP/CPPS. 
I described the acute analgesic responses of bradykinin B2 receptor 
antagonist against testicular damage and inflammation in rats but didn’t uncover its 
effect on chronic inflammatory pain nor on bladder overactivity associated with 
testicular pain. Although the experimental conditions used in this study may differ 
from those of clinical settings involving patients, my present findings suggest that 
the inhibition of bradykinin-bradykinin B2 receptor signaling may be a novel target 
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for treating urogenital pain in CP/CPPS in which an increase in intraprostatic 
bradykinin level is indicated. 
Here, I found that intratesticular bradykinin evokes pain behavior via 
stimulation of bradykinin B2 receptors and that intratesticular acetic acid injection 
induces intratesticular bradykinin synthesis, consequently leading to pain behavior. 
These findings suggest that the potential utility of bradykinin B2 receptor 
antagonists as a novel target for treating urogenital pain. 
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Figure 11. Typical pain behaviors observed after intratesticular injection of 
bradykinin or 1% acetic acid 
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Figure 12. Number of pain behaviors (mean ± S.E.M., n=4-6); (a) 0-10 min and (b) 
10-20 min after testicular injection of aqueous solution of 0.1, 0.3, 1, 3, or 
10 mmol/L bradykinin. 
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Figure 13. Number of pain behaviors (mean ± S.E.M., n=6-8) 0-10 min after 
intratesticular injection of aqueous solution of 1 mmol/L bradykinin under 
pretreatment with either FK3657 [1, 3, 10, or 30 mg/kg per os (p.o.)] or its vehicle 
15 min before bradykinin injection. * P < 0.05, ** P < 0.01 vs. vehicle group by 
Dunnet’s multiple comparison test. 
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Figure 14. Number of pain behaviors (mean ± S.E.M., n=7-15) 5-20 min after 
intratesticular injection of 1% acetic acid under pretreatment with either FK3657 
(1, 3, 10, or 30 mg/kg p.o.) or its vehicle 10 min before acetic acid injection.  
** P < 0.01 vs. vehicle group by Dunnet’s multiple comparison test. 
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Figure 15 Concentration of intratesticular bradykinin (ng/g-tissue, mean ± 
S.E.M., n=4) at 5, 20, 40, and 60 min after injection of 1% acetic acid or DW. 
Statistical analysis was only performed at 20 min after injection. ** P < 0.01 vs DW 
group by Student’s t-test. 
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Conclusions  
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In the present study, bradykinin elicited human urethral smooth muscle 
contraction and an increase in urethral pressure in anesthetized rats and dogs 
through the bradykinin B2 receptor. Furthermore, bradykinin, which was produced 
in the testes by testicular injection of bradykinin or acetic acid, elicited pain 
behaviors in rats through the bradykinin B2 receptor. Therefore, these findings 
suggest that bradykinin is involved in LUTS such as voiding symptoms and 
urogenital pain and potential utility of bradykinin B2 receptor antagonists as a novel 
target for treating LUTS. 
Generation or formation of BPH has not been fully elucidated. In addition, 
prostate weight and the degree of voiding dysfunction are not necessarily 
proportional in the actual clinical settings and it is considered that its generation or 
the progress of symptoms is affected by a number of factors. Especially from the 
fact that infiltration of inflammatory cells is frequently found in the prostate of 
symptomatic BPH patients, chronic inflammation as a factor other than the 
androgen is also believed to play an important role in the induction of BPH or 
symptoms. BPH patients have been reported to have 7.7-folds history of prostatitis 
(Collins et al., 2002). It has been reported that about 20% of BPH patients showed 
ejaculation pain or discomfort and patients with symptoms have a strong degree of 
LUTS (Nickel et al., 2005). Also, it is known that prostatitis as well as BPH are 
common in the elderly (Pontari, 2003). Therefore, it has become clearer from some 
relevant reports that there is some relation between prostatitis and LUTS or BPH. 
Prostatitis conventionally been considered syndrome consist of a number 
of etiologies rather than a single disease. In particular, category III is classified as 
CP/CPPS and category IV as asymptomatic inflammatory prostatitis (Krieger et al., 
1999). Conventionally this category IV was not considered a clinical problem nor 
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treatment target. However, it has been found that a presence of inflammation is 
associated with the progression and urinary symptoms of BPH in some large-scale 
clinical trials such as “Reduction by Dutasteride of Prostate Cancer Events 
(REDUCE)” trial and “Medical Therapy of Prostatic Symptoms (MTOPS)” trial. 
For example, in the REDUCE trial, histological chronic inflammation has been 
reported in approximately 78% of BPH patients regardless of the symptoms 
associated with chronic prostatitis (Nickel et al., 2007, Nickel et al., 2008). In 
addition, in the investigation over the average 4.5-years follow-up in MTOPS trial, 
the rate at which BPH patients lead to acute urinary retention was significantly 
higher in the group with inflammation. In other words, the group with histological 
inflammation tends to progress symptoms and the presence of inflammation is 
considered to be a predictor of BPH progression (Crawford et al., 2006). On the 
other hand, the pathological analysis of the excised tissue of symptomatic BPH 
patients without inflammation who underwent trans-urethral resection (TURP) of 
the prostate showed infiltration of inflammatory cells in almost all cases (Nickel et 
al., 1999). From these reports, it would be more or less true that the category IV 
prostatitis would be involved in manifestations of BPH. 
Changes in molecular background associated with chronic prostatitis are 
considered to play an important role in the mechanism of manifestation caused by 
BPH. Etiology of asymptomatic prostatitis is considered possibility of infection of 
bacteria or viruses, allergic reaction mechanisms caused by stimulation of semen or 
urine and induction of inflammatory cells by estrogen. In recent years, BPH is also 
considered as localized autoimmune diseases, that is, weakening of the immune 
system due to aging or changes in the hormonal environment causes a reduced 
function of suppressor cells, infiltration of inflammatory cells and then chronic 
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inflammation. Chronic inflammation would repeat tissue damages, healing and 
regeneration and lead to an increase in prostate nodule and at the same time, 
transformation of stroma into some form of tissue may induce symptomatic BPH 
(Kramer et al., 2007, Untergasser et al., 2005) (Figure 16). 
It is possible in the future that new therapeutic strategies for LUTS 
associated with BPH are established by further elucidating the meaning of 
inflammation in the prostate from molecular biology perspective. In the present 
study, I focused on bradykinin which is known to be produced upon the 
inflammation or tissue damage and examined its involvement in LUTS such as 
voiding symptoms or urogenital pain. There is also a report that bradykinin is 
involved in proliferation of prostate stromal cells (Walden et al., 1999), and thus 
bradykinin produced by inflammation in the prostate may be involved in the 
manifestation and progression of BPH. These speculations suggest that bradykinin 
B2 receptor antagonists would be useful for an inhibition of the progression of BPH 
as well as for treatment of LUTS such as voiding symptoms or urogenital pain 
(Figures 17, 18). 
As the bradykinin B2 receptor antagonists, Icatibant (Hoe-140), peptide 
formulation (injection), has been launched for an indication of hereditary 
angioedema, a rare disease, but oral drugs of low molecule (non-peptide) have not 
yet been available for any indications including urology or genital diseases. 
Currently, α1-blockers are used for drug therapy of BPH as standard of care but 5α-
reductase inhibitors are added on top of α1-blockers when the therapeutic effect of 
the blocker is insufficient and when prostate volume is greater than usual. Recently, 
PED5 inhibitors were also launched as a new alternative choice but a single 
therapeutic agent useful for suppression of pathology progression as well as LUTS 
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has not yet been obtained. As for the treatment for CP/CPPS, any therapeutic agent 
has not been available and further research or development is expected in the future 
considering its high unmet medical needs. In addition to testicular pain models 
examined in my study, there are many reports that bradykinin B2 receptor 
antagonists are effective in variety of pain models in animals. Based on such a 
background, the present study is expected to contribute to providing a new 
therapeutic option or possibility for the future of urology and genital disease 
treatment or even broader therapeutic areas. 
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Figure 16. Hypothesis about relation between inflammation (immune response) 
and prostatic proliferation (Kramer et al., 2007) 
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Figure 17. Bradykinin induces urethral smooth muscle contraction, pain in 
genitourinary tract, proliferation in prostate stroma and inflammation via 
bradykinin B2 receptors 
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Figure 18. Potential utility of bradykinin B2 receptor antagonists 
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